ALPHAEON Corporation, a wholly owned subsidiary of Strathspey Crown Holdings, has acquired an exclusive United States license for Geneva-based TEOXANE Laboratories’ full line of cosmeceuticals and hyaluronic acid-based dermal filler products, which are currently available in 90 markets outside of the United States.
"The partnership with TEOXANE Laboratories is a great fit for ALPHAEON, as both companies possess an unparalleled commitment to delivering science-based, high-quality medical aesthetic products," said Robert E. Grant, CEO of ALPHAEON. "During the past 10 years, TEOXANE has gained significant market presence and leadership in Europe, capturing the number two market position in several western European countries for its broad range of next-generation hyaluronic acid dermal fillers and innovative cosmeceuticals. The TEOXANE transaction advances ALPHAEON's vision to bring highly innovative lifestyle healthcare products, combined with value-added services, to serve patients."
TEOXANE founder and chairwoman Valerie Taupin will join the ALPHAEON Board of Directors. "Physicians in the United States have been asking us to bring our innovative products to the U.S. market for many years," said Taupin. "ALPHAEON brings together an impressive team of medical aesthetic leaders who share TEOXANE's commitment to excellence, innovation and patient satisfaction.”